Loading clinical trials...
Loading clinical trials...
Study to Evaluate the Anti-emetic Effect of Aprepitant as an add-on Therapy in Children and Adolescents Receiving AML Remission Induction Chemotherapy: An Investigator-initiated, Randomized, Open Label Trial
Conditions
Interventions
Aprepitant
Ondansetron
+1 more
Locations
1
India
Irch, Aiims , New Delhi , India
New Delhi, DEL, India
Start Date
November 1, 2016
Primary Completion Date
June 1, 2018
Completion Date
December 1, 2018
Last Updated
January 25, 2017
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT04628026
NCT06484062
Lead Sponsor
Dr Atul Sharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions